AIM To determine if the drug doses and administration schedules of carboplatin and gemcitabine combination affect antitumor effects. MATERIALS AND METHODS The inhibition of cell viability was measured by MTT assay. Median effect analysis was conducted to determine the cytotoxicity activity of carboplatin and gemcitabine combination. Cell cycle changes were analyzed by flow cytometry. RESULT...

Ovarian cancer is the leading cause of death of women worldwide. Because ovaries are intra-abdominal organs, and as there is still no effective screening tool for ovarian cancer, the majority of patients who present are in the advanced stages of the disease (Carter et al., 1997). Surgical exploration is necessary to obtain tissue for histologic study, staging, and hopefully for optimal surgery....

The breast cancer susceptibility gene 1 (BRCA1) has been shown to maintain genomic stability through multiple functions in the regulation of DNA damage repair and transcription. Its translated BRCT (BRCA1 C-terminal domain) acts as a strong transcriptional activator. BRCA1 damaged by carboplatin treatment may lead to a loss of such functions. To address the possibility of the BRCA1 gene as a th...

Hyperthermic enhancement of cis-diammine-l,l-cyclobutane dicarboxylate platinum(II) (carboplatin) cytotoxicity was studied in vitro in .IM, a human acute lyntphoblastic leukemia cell line. Corrected for direct heat toxicity, hyperthermia enhanced carboplatin killing at the clinically relevant temperatures of 40.5°and 41.8°C.The thermal enhancement ratios at these temperatures were 1.89 and 33...

We currently use Convection-Enhanced Delivery (CED) of the platinum-based drug, carboplatin as a novel treatment strategy for high grade glioblastoma in adults and children. Although initial results show promise, carboplatin is not specifically toxic to tumour cells and has been associated with neurotoxicity at high infused concentrations in pre-clinical studies. Our treatment strategy requires...

When carboplatin (cis-diammine-1,1-cyclobutane-dicarboxylato-platinum) delivery to brain tumors is optimized with osmotic blood-brain barrier disruption (BBBD), high frequency hearing loss can result. Treatment with sodium thiosulfate (STS) blocked carboplatin cytotoxicity against the LX-1 human small cell lung carcinoma cell line in vitro. STS decreased carboplatin-induced ototoxicity in a gui...

How nephrotoxic is carboplatin? Sir-The study by Sleijfer et al. (1989) reports on a significant deterioration in renal function following moderate dose carboplatin-with a 19% reduction in glomerular filtration rate. This raises reservations about the claimed advantages of carboplatin over cisplatin and suggests that not only is close monitoring of renal function necessary, but also that hyperh...

BACKGROUND Anthracycline-based regimens have a limited role in patients with metastatic breast cancer due to cumulative cardiotoxicity and their common use in adjuvant chemotherapy. New nonanthracycline regimens are, therefore, needed for metastatic disease. Single-agent carboplatin is active in patients with previously untreated metastatic breast cancer, producing response rates of 20%-35%. Pr...

We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies. All women with pathologically documented ovarian, fallopian tube, or primary peritoneal cancer treated with carboplatin alone or a carboplatin-based combination chemotherapy regimen at a single hospital between January 2006 and Decemb...